Advertisement

Diabetologia

, Volume 59, Issue 8, pp 1616–1620 | Cite as

Angiopoietins and diabetic nephropathy

  • Luigi GnudiEmail author
Open Access
Mini-Review

Abstract

Diabetic nephropathy is the main cause of end-stage renal failure in the Western world. In diabetes, metabolic and haemodynamic perturbations disrupt the integrity of the glomerular filtration barrier, leading to ultrastructural alterations of the glomeruli, including podocyte foot process fusion and detachment, glomerular basement membrane thickening, reduced endothelial cell glycocalyx, and mesangial extracellular matrix accumulation and glomerulosclerosis, ultimately leading to albuminuria and end-stage renal disease. Many vascular growth factors, such as angiopoietins, are implicated in glomerular biology. In normal physiology angiopoietins regulate the function of the glomerular filtration barrier. When they are dysregulated, however, as they are in diabetes, they drive the cellular mechanisms that mediate diabetic glomerular pathology. Modulation of angiopoietins expression and signalling has been proposed as a tool to correct the cellular mechanisms involved in the pathophysiology of diabetic microvascular disease, such as retinopathy in humans. Future work might evaluate whether this novel therapeutic approach should be extended to diabetic kidney disease.

Keywords

Albuminuria Angiopoietin Endothelial cells Diabetes Glomerulus Review 

Abbreviations

ANGPT1

Angiopoietin 1

ANGPT2

Angiopoietin 2

GBM

Glomerular basement membrane

TIE-2

Tyrosine kinase with immunoglobulin and epidermal growth factor homology domain-2

VEGFA

Vascular endothelial growth factor A

Introduction

Angiopoietins are vascular growth factors involved in vasculogenesis and vascular repair. Two major isoforms regulate vascular homeostasis, namely angiopoietin 1 (ANGPT1) and angiopoietin 2 (ANGPT2). ANGPT1, by binding to its receptor tyrosine kinase with immunoglobulin and epidermal growth factor homology domain-2 (TIE-2), stabilises the vessel wall, while ANGPT2, by either interacting with integrins or competing with ANGPT1-TIE-2 receptor binding (inhibiting ANGPT1-mediated TIE-2 phosphorylation), promotes vessel wall destabilisation and favours, in the presence of vascular endothelial growth factor A (VEGFA), endothelial cell proliferation and new vessel formation.

Angiopoietins play an important role in the glomerular capillaries in both physiology and disease. Glomerular capillaries are unique in their structure: they are composed of a fenestrated endothelium, which sits on a basement membrane, and specialised epithelial cells (the podocytes), which cover the external layers of the glomerular filter with their interdigitating foot processes.

In recent years, work by different investigators has highlighted the presence of an autocrine/paracrine network consisting of angiopoietins and other vasoactive peptides regulating the physiology of the glomerular capillaries in terms of blood flow and permeability of the vascular wall. An imbalance in these vasoactive peptides promotes endothelial dysfunction: one of the earliest mechanisms of vascular chronic complications in diabetes.

This brief review focuses on the role of angiopoietins in physiology and how an angiopoietin imbalance could contribute to the pathophysiology of diabetic glomerulopathy.

Glomerular capillary function is regulated by vasoactive peptides within an epithelial–endothelial autocrine/paracrine system

The kidney glomerulus filters the blood to generate urine by retaining cells and macromolecules. The adult glomerulus consists of specialised capillaries composed of epithelial cells (podocytes) separated from the endothelium and mesangium by a thin glomerular basement membrane (GBM) [1]. All the components of the glomerular filtration barrier participate in the maintenance of the permselective properties of the glomerular capillaries. Podocyte cells are composed of a major cell body from which specialised foot processes depart to interdigitate and form slit diaphragms [2], a specialised tight junction (composed of proteins such as nephrin and podocin) that represents one of the major size-selective barriers in the glomerular capillaries preventing macromolecular passage into the pre-urine [3, 4]. The glomerular endothelial cells are fenestrated; the fenestrae are characterised by a unique ultrastructure lacking diaphragms [5, 6] and facilitate high permeability to water and small solutes [7]. The luminal side of the glomerular endothelial cells is covered by a thin glycocalyx consisting of proteoglycans [7], which are also believed to contribute to the permselective properties of the glomerular capillary [8]. The GBM also contributes to the permeability of the glomerular capillary, and alteration of its structure affects its ability to restrict both water [7] and protein [9] filtration through the glomerular barrier.

Many recent studies have proposed a complex local autocrine/paracrine network consisting of vascular growth factors and vasoactive peptides secreted by glomerular cells which exert their action by binding to their specific receptor on podocytes and glomerular endothelial cells. The specific balance of different growth factors such as angiopoietins and VEGFA and their interaction have been recognised as crucial mechanisms in the maintenance of a healthy glomerulus; conversely, their imbalance has been shown to drive the early pathological manifestations of diabetic glomerular disease.

Angiopoietins

Angiopoietins are vascular growth factors that promote the formation of blood vessels. ANGPT1 and ANGPT2 are the most studied angiopoietins [10]. ANGPT1 is the major physiological ligand and activator (via phosphorylation) of the TIE-2 receptor [11, 12]. ANGPT1 is extremely important in early vasculature growth up to embryonic days 9.5–12.5 [13, 14]. Studies also suggest that ANGPT1 is important in maintaining the stability (and permeability) of the mature vasculature [15, 16]. This concept has, however, been challenged by studies in mice with inducible global deletion of Angpt1 from embryonic day 13.5 [14], in which animals were viable and presented with no overt phenotype [14].

ANGPT2 has opposing actions to ANGPT1 and promotes blood vessel wall destabilisation [17], not only by competitive inhibition of the binding of ANGPT1 to TIE-2, hence reducing TIE-2 activation and phosphorylation [17], but also via integrin activation [18]. The biological effects of ANGPT2 appear to be dependent on the ambient levels of VEGFA: ANGPT2 leads to vessel regression when VEGFA expression/levels are low or absent, but participates in the process of angiogenesis in the presence of high levels of surrounding VEGFA [17]. Studies have shown that VEGFA inhibits ANGPT1–TIE-2 signalling via TIE-2 shedding, promoting, in concert with ANGPT2-mediated TIE-2 signalling inhibition, new vessel formation [19].

In the kidney glomerulus, Angpt1 is constitutively expressed in podocytes [20, 21], while Angpt2 is transiently detected during development in the mesangial cells [22], but is then not expressed, or expressed at a very low level, in the adult glomerulus in normal physiology. Tie2 (also known as Tek) expression is localised in developing and adult mouse glomerular capillaries mainly at the level of the endothelium [20, 23], while some reports show its expression in mouse and rat podocytes in vivo [21, 24].

Angiopoietins and diabetic glomerulopathy

The expression of angiopoietins in glomerular disease has been investigated in different experimental animal models of diabetes. In rats injected with streptozotocin, whole-kidney Angpt1 and Angpt2 mRNA and protein increase at 4 weeks’ diabetes duration, but after 8 weeks ANGPT1 levels diminish, while ANGPT2 remains elevated [25]. In another study, whole glomeruli or glomerular endothelial cells isolated from diabetic mice showed raised Angpt2 mRNA levels compared with non-diabetic animals, while no changes were observed in Angpt1 in the whole glomerulus [14].

Transgenic mouse studies have demonstrated that raised Angpt2 leads to a phenotype similar to that seen in diabetic glomerular disease. Indeed, inducible podocyte-specific overexpression of Angpt2, increasing the ANGPT2/ANGPT1 ratio in otherwise normal healthy adult mice, leads to albuminuria and glomerular endothelial apoptosis, a phenotype paralleled by downregulation of VEGFA and nephrin protein expression [26]. Similarly, ANGPT2 has been shown to activate β1-integrin, resulting in destabilisation of endothelial cell intercellular junctions via an increase in cell contractility and alteration of pericellular matrix remodelling [18].

Parallel work from our group has shown that, in the very early stages of diabetic glomerulopathy (3 weeks’ diabetes duration), glomerular Angpt1 mRNA decreases in diabetic mice, with no significant changes in Angpt2 mRNA levels, when compared with non-diabetic animals [24]. This apparent acute effect of elevated circulating glucose levels was also observed in vitro when Angpt1 mRNA was significantly downregulated in high-glucose-treated podocytes compared with normal-glucose-treated cells [24]. Overall, these observations are consistent with the contention that an increased ratio of ANGPT2/ANGPT1 could play a role in the development and progression of glomerular disease in diabetes (Fig. 1).
Fig. 1

ANGPT2/ANGPT1 imbalance is paralleled by capillary destabilisation. ANGPT1 is downregulated in early diabetic kidney disease, leading to diabetes-mediated angiopoietin imbalance (ANGPT2 > ANGPT1); ANGPT2 excess results in proteinuria. Repletion of ANGPT1 restores angiopoietin balance (ANGPT1 > ANGPT2) and, acting as a ‘brake’ on vascular lesions, prevents albuminuria and glomerular structural lesions in the early phases of diabetic glomerular disease. Red arrows indicate changes favouring progression towards vascular disease, green arrows point towards changes stimulating a healthy vessel

Studies using genetically modified mice have further helped towards the understanding of angiopoietins in diabetic glomerular disease. Global deletion of Angpt1 from embryonic day 16.5 (to circumvent any adverse effects on early vascular development) is paralleled, in mice at 20 weeks’ diabetes duration, by increases in albuminuria and mesangial matrix expansion and glomerulosclerosis [14], suggesting that Angpt1 expression levels are important in the pathophysiology of diabetic glomerular disease and could confer protection against high-glucose-mediated glomerular capillary injury, serving as a ‘brake’ on vascular lesions.

To further explore this possibility we restored the ANGPT1 deficiency found in early diabetic glomerulopathy using transgenic mice overexpressing Angpt1, specifically in the glomeruli, again with an inducible system [24]. Podocyte-specific ANGPT1 overexpression/repletion in the adult diabetic mouse led to a reduction in albuminuria [24] and downregulation of diabetes-induced VEGFA signalling. The combination of high ANGPT1 levels and low VEGFA signalling in diabetic nephropathy is likely to represent an important mechanism that favours a more stable capillary wall, a phenomenon that we described as paralleled by a reduction in glomerular endothelial cell proliferation, as seen in the early stages of diabetic nephropathy [27], and a reduction in albumin excretion [24].

Overexpression/repletion of ANGPT1 in diabetic mice increased the phosphorylation of endothelial nitric oxide synthase on serine residue 1177 [24], an effect that may increase nitric oxide [28] and lead to a more stable, less permeable vascular wall [29, 30]. ANGPT1 repletion was also accompanied by a reduction in diabetes-induced nephrin phosphorylation [24], an event paralleled by reduced nephrin degradation and improved foot processes in the podocyte cytoskeleton/structure, leading to a more intact and functional glomerular filtration barrier [31].

ANGPT2 mRNA was found to be elevated in isolated glomeruli from patients with diabetes when compared with live donor kidneys, while no change was observed in ANGPT1 expression [24]. Importantly, poor glycaemic control is paralleled by high circulating ANGPT2 levels in patients with type 2 diabetes. ANGPT2 levels are also associated with indexes of endothelial damage/dysfunction, regardless of vascular disease [32]. Similarly, urinary ANGPT2 levels are increased in patients with type 2 diabetes with renal damage and are associated with albuminuria [33].

A recent study reported preliminary evidence that ANGPT2 is an independent predictor of adverse renal outcome in chronic kidney disease in both the general and the diabetic population [34]. Of interest, raised ANGPT2 levels are associated with systemic markers of inflammation in patients with chronic kidney disease and are predictors of mortality [35]. For example, increased aortic stiffness is known to be a powerful independent predictor of mortality in individuals with type 2 diabetes [36], and recent work has shown that plasma ANGPT2 is associated with arterial stiffness in patients with chronic kidney disease [37]. Indeed, an imbalance in favour of ANGPT2 would promote inflammation and fibrosis, with macrophages as key players in stimulating collagen-rich extracellular matrix synthesis by vascular smooth muscle cells with stiffening of the vascular wall [38].

Taking all these observations together, it is quite evident that a tightly controlled angiopoietin TIE-2 receptor system is required for the development and maintenance of a healthy microvasculature and glomerular filtration barrier. Disruption of the ANGPT2/ANGPT1 balance in favour of ANGPT2 leads to destabilisation of the capillary walls and an increase in inflammation and vascular permeability, promoting microvascular disease.

Manipulation of local and systemic angiopoietins could represent an attractive therapeutic target for patients with diabetic microvascular complications [39, 40]. Early studies in patients with diabetes with macular oedema have shown that administration of AKB-9778 (a vascular endothelial-protein tyrosine phosphatase that promotes TIE-2 receptor activation) for 4 weeks reduced macular oedema and improved vision, without demonstrating any safety concerns [41]. Future studies might address the role of TIE-2 activation in diabetic glomerular disease.

Notes

Acknowledgements

This work was supported by Diabetes UK (grant no. 08/0003695) and EFSD/Servier.

Duality of interest

The author declares that there is no duality of interest associated with this manuscript.

Contribution statement

The author was the sole contributor to this paper.

References

  1. 1.
    Tryggvason K, Pikkarainen T, Patrakka J (2006) Nck links nephrin to actin in kidney podocytes. Cell 125:221–224CrossRefPubMedGoogle Scholar
  2. 2.
    Greka A, Mundel P (2012) Cell biology and pathology of podocytes. Annu Rev Physiol 74:299–323CrossRefPubMedGoogle Scholar
  3. 3.
    Boute N, Gribouval O, Roselli S et al (2000) NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 24:349–354CrossRefPubMedGoogle Scholar
  4. 4.
    Kestila M, Lenkkeri U, Mannikko M et al (1998) Positionally cloned gene for a novel glomerular protein—nephrin—is mutated in congenital nephrotic syndrome. Mol Cell 1:575–582CrossRefPubMedGoogle Scholar
  5. 5.
    Ichimura K, Stan RV, Kurihara H, Sakai T (2008) Glomerular endothelial cells form diaphragms during development and pathologic conditions. J Am Soc Nephrol 19:1463–1471CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Brunskill EW, Potter SS (2010) Gene expression programs of mouse endothelial cells in kidney development and disease. PLoS One 5, e12034CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Haraldsson B, Nystrom J, Deen WM (2008) Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 88:451–487CrossRefPubMedGoogle Scholar
  8. 8.
    Salmon AH, Ferguson JK, Burford JL et al (2012) Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction. J Am Soc Nephrol 23:1339–1350CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Suh JH, Miner JH (2013) The glomerular basement membrane as a barrier to albumin. Nat Rev Nephrol 9:470–477CrossRefPubMedGoogle Scholar
  10. 10.
    Woolf AS, Gnudi L, Long DA (2009) Roles of angiopoietins in kidney development and disease. J Am Soc Nephrol 20:239–244CrossRefPubMedGoogle Scholar
  11. 11.
    Kim KT, Choi HH, Steinmetz MO et al (2005) Oligomerization and multimerization are critical for angiopoietin-1 to bind and phosphorylate Tie2. J Biol Chem 280:20126–20131CrossRefPubMedGoogle Scholar
  12. 12.
    Brindle NP, Saharinen P, Alitalo K (2006) Signaling and functions of angiopoietin-1 in vascular protection. Circ Res 98:1014–1023CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Suri C, Jones PF, Patan S et al (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87:1171–1180CrossRefPubMedGoogle Scholar
  14. 14.
    Jeansson M, Gawlik A, Anderson G et al (2011) Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J Clin Invest 121:2278–2289CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Gavard J, Patel V, Gutkind JS (2008) Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Dev Cell 14:25–36CrossRefPubMedGoogle Scholar
  16. 16.
    Thurston G, Suri C, Smith K et al (1999) Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286:2511–2514CrossRefPubMedGoogle Scholar
  17. 17.
    Maisonpierre PC, Suri C, Jones PF et al (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55–60CrossRefPubMedGoogle Scholar
  18. 18.
    Hakanpaa L, Sipila T, Leppanen VM et al (2015) Endothelial destabilization by angiopoietin-2 via integrin beta1 activation. Nat Commun 6:5962CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Findley CM, Cudmore MJ, Ahmed A, Kontos CD (2007) VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling. Arterioscler Thromb Vasc Biol 27:2619–2626CrossRefPubMedGoogle Scholar
  20. 20.
    Yuan HT, Suri C, Yancopoulos GD, Woolf AS (1999) Expression of angiopoietin-1, angiopoietin-2, and the Tie-2 receptor tyrosine kinase during mouse kidney maturation. J Am Soc Nephrol 10:1722–1736PubMedGoogle Scholar
  21. 21.
    Satchell SC, Harper SJ, Tooke JE, Kerjaschki D, Saleem MA, Mathieson PW (2002) Human podocytes express angiopoietin 1, a potential regulator of glomerular vascular endothelial growth factor. J Am Soc Nephrol 13:544–550PubMedGoogle Scholar
  22. 22.
    Yuan HT, Suri C, Landon DN, Yancopoulos GD, Woolf AS (2000) Angiopoietin-2 is a site-specific factor in differentiation of mouse renal vasculature. J Am Soc Nephrol 11:1055–1066PubMedGoogle Scholar
  23. 23.
    Long DA, Woolf AS, Suda T, Yuan HT (2001) Increased renal angiopoietin-1 expression in folic acid-induced nephrotoxicity in mice. J Am Soc Nephrol 12:2721–2731PubMedGoogle Scholar
  24. 24.
    Dessapt-Baradez C, Woolf AS, White KE et al (2014) Targeted glomerular angiopoietin-1 therapy for early diabetic kidney disease. J Am Soc Nephrol 25:33–42CrossRefPubMedGoogle Scholar
  25. 25.
    Rizkalla B, Forbes JM, Cao Z, Boner G, Cooper ME (2005) Temporal renal expression of angiogenic growth factors and their receptors in experimental diabetes: role of the renin-angiotensin system. J Hypertens 23:153–164CrossRefPubMedGoogle Scholar
  26. 26.
    Davis B, Dei CA, Long DA et al (2007) Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia. J Am Soc Nephrol 18:2320–2329CrossRefPubMedGoogle Scholar
  27. 27.
    Nakagawa T, Kosugi T, Haneda M, Rivard CJ, Long DA (2009) Abnormal angiogenesis in diabetic nephropathy. Diabetes 58:1471–1478CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Babaei S, Teichert-Kuliszewska K, Zhang Q, Jones N, Dumont DJ, Stewart DJ (2003) Angiogenic actions of angiopoietin-1 require endothelium-derived nitric oxide. Am J Pathol 162:1927–1936CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Predescu D, Predescu S, Shimizu J, Miyawaki-Shimizu K, Malik AB (2005) Constitutive eNOS-derived nitric oxide is a determinant of endothelial junctional integrity. Am J Physiol Lung Cell Mol Physiol 289:L371–381CrossRefPubMedGoogle Scholar
  30. 30.
    Nakagawa T (2007) Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol Renal Physiol 292:F1665–F1672CrossRefPubMedGoogle Scholar
  31. 31.
    Zhu J, Sun N, Aoudjit L et al (2008) Nephrin mediates actin reorganization via phosphoinositide 3-kinase in podocytes. Kidney Int 73:556–566CrossRefPubMedGoogle Scholar
  32. 32.
    Lim HS, Blann AD, Chong AY, Freestone B, Lip GY (2004) Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care 27:2918–2924CrossRefPubMedGoogle Scholar
  33. 33.
    Chen S, Li H, Zhang C et al (2015) Urinary angiopoietin-2 is associated with albuminuria in patients with type 2 diabetes mellitus. Int J Endocrinol 2015:163120PubMedPubMedCentralGoogle Scholar
  34. 34.
    Tsai YC, Chiu YW, Tsai JC et al (2014) Association of angiopoietin-2 with renal outcome in chronic kidney disease. PLoS One 9, e108862CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    David S, John SG, Jefferies HJ et al (2012) Angiopoietin-2 levels predict mortality in CKD patients. Nephrol Dial Transplant 27:1867–1872CrossRefPubMedGoogle Scholar
  36. 36.
    Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG (2002) Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 106:2085–2090CrossRefPubMedGoogle Scholar
  37. 37.
    Chang FC, Chiang WC, Tsai MH et al (2014) Angiopoietin-2-induced arterial stiffness in CKD. J Am Soc Nephrol 25:1198–1209CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Saharinen P, Alitalo K (2011) The yin, the yang, and the angiopoietin-1. J Clin Invest 121:2157–2159CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Dei Cas A, Gnudi L (2012) VEGF and angiopoietins in diabetic glomerulopathy: how far for a new treatment? Metabolism 61:1666–1673CrossRefPubMedGoogle Scholar
  40. 40.
    Gnudi L, Benedetti S, Woolf AS, Long DA (2015) Vascular growth factors play critical roles in kidney glomeruli. Clin Sci (Lond) 129:1225–1236CrossRefGoogle Scholar
  41. 41.
    Campochiaro PA, Sophie R, Tolentino M et al (2015) Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2. Ophthalmology 122:545–554CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2016

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Unit for Metabolic Medicine, Cardiovascular Division, Faculty of Life Science & MedicineKing’s College LondonLondonUK

Personalised recommendations